Biotech: Page
-
Getty Images
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.
By BioPharma Dive staff • June 7, 2024 -
Warren Little via Getty Images
GSK acquires oligonucleotide drug startup Elsie
The deal, worth up to $50 million, adds to a pipeline GSK is building around nucleic acid drugs, including its hepatitis B candidate bepirovirsen.
By Delilah Alvarado • June 6, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Gwendolyn Wu/BioPharma Dive
As biotech recovers, venture firms’ preferences appear to shift
Venture investment into U.S. biotechs is back at pre-COVID levels. But firms seem more selective in the companies they favor, and some are looking toward M&A rather than IPOs for an exit.
By Gwendolyn Wu • Updated June 6, 2024 -
Getty Images
Germany’s ITM raises $205M as radiopharma field booms
The funding will help ITM advance a pipeline that includes a potential competitor to Novartis' neuroendocrine cancer treatment Lutathera.
By Ned Pagliarulo • June 6, 2024 -
Getty Images
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.
By BioPharma Dive staff • June 5, 2024 -
Getty Images
Viking says biopsy data confirm MASH drug’s benefit
The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.
By Jonathan Gardner • June 4, 2024 -
Spencer Platt via Getty Images
Structure pill leads to competitive weight loss in obesity study
Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly.
By Delilah Alvarado • June 3, 2024 -
Getty Images
ALS drug developmentEli Lilly adds ALS drug prospect with QurAlis deal
The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.
By Gwendolyn Wu • June 3, 2024 -
Getty Images
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
Regeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over Keytruda and Neurocrine’s longtime CEO revealed plans to step down.
By BioPharma Dive staff • May 31, 2024 -
Getty Images
Immunovant changes up plans for closely watched autoimmune drugs
The company is prioritizing development of an earlier so-called FcRn inhibitor, a type of medicine that’s shown promise treating multiple inflammatory conditions.
By Kristin Jensen • May 30, 2024 -
Getty Images
CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs
The $73 million round for CinRx Pharma, which created a startup AstraZeneca bought last year, will help fund subsidiaries making drugs for obesity, irritable bowel syndrome and gastroparesis.
By Gwendolyn Wu • May 30, 2024 -
Getty Images
A biotech working on a new approach to IVF raises $33M in fresh funding
The Series B funding from Two Sigma Ventures, RA Capital and others will help Gameto develop technology it says could replace hormonal injections and shorten the IVF process.
By Delilah Alvarado • May 29, 2024 -
Getty Images
Merck to buy eye drug developer for $1.3B
An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
By Kristin Jensen • May 29, 2024 -
Getty Images
Can robots break the cell therapy bottleneck?
A partnership between cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could address manufacturing hurdles, the CEOs said.
By Michael Gibney • May 29, 2024 -
Elizabeth Regan/BioPharma Dive
Insmed shares double as lung drug data convince Wall Street
After reporting positive clinical trial results for its drug brensocatib, Insmed plans to later this year file for U.S. approval in bronchiectasis that’s not associated with cystic fibrosis.
By Ned Pagliarulo • May 28, 2024 -
Getty Images
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
The deal involves royalties for a brain cancer drug Agios previously sold off and that Royalty Pharma thinks could generate more than $1 billion in U.S. sales.
By Delilah Alvarado • May 28, 2024 -
Getty Images
Roche’s Sabry retires; Duchenne drug fails confirmatory test
The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.
By BioPharma Dive staff • May 28, 2024 -
Getty Images
Orna, a circular RNA specialist, acquires a buzzy startup
After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.
By Jacob Bell • May 23, 2024 -
Michael M. Santiago via Getty Images
Cytokinetics secures up to $575M in royalty deal, frustrating investors
The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said.
By Ned Pagliarulo • May 23, 2024 -
Permission granted by Biogen
Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B
The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching out beyond the neurological drugs that have long been its focus.
By Kristin Jensen • May 22, 2024 -
Getty Images
Regeneron faces new biosimilar threats; an AI biotech lays off staff
Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers.
By BioPharma Dive staff • May 22, 2024 -
Permission granted by SixPeaks Bio AG
SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca
AstraZeneca has an exclusive chance to buy the startup, which is developing a muscle-protecting weight loss medicine, within the next two years.
By Gwendolyn Wu • May 22, 2024 -
Scott Olson via Getty Images
Lilly partners with Aktis, deepening radiopharma investment
The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.
By Delilah Alvarado • May 21, 2024 -
Permission granted by AltruBio
AltruBio lands up to $225M after shift to immune drug research
Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.
By Gwendolyn Wu • May 21, 2024 -
Permission granted by Pheon Therapeutics
Pheon rides wave of ADC interest with $120M financing
CEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody-drug conjugates, though it’s keeping details close.
By Gwendolyn Wu • May 21, 2024
Previous
